telmisartan has been researched along with Disease Exacerbation in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (37.14) | 29.6817 |
| 2010's | 21 (60.00) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Dalman, RL; Fitridge, R; Golledge, J; Jenkins, JS; Lindeman, JH; McDonnell, L; Morris, DR; Moxon, JV; Pinchbeck, J; Rowbotham, SE; Singh, TP; Tomee, SM | 1 |
| Dalman, RL; Iida, Y; Miyata, M; Xu, B; Xuan, H | 1 |
| Chai, Q; Chen, Y; Cui, Y; Dong, Y; Duan, D; Gong, G; Hu, W; Ji, T; Liu, Z; Sheng, L; Sun, S; Wang, J; Zhang, H; Zhao, Y; Zhou, T | 1 |
| Kurinami, H; Morishita, R; Nakagami, H; Sato, N; Shimamura, M | 1 |
| Clase, CM; Dehghan, M; Dunkler, D; Gao, P; Heinze, G; Kohl, M; Mann, JF; Oberbauer, R; Teo, KK; Yusuf, S | 1 |
| Sharma, K; Sweiss, N | 1 |
| Chen, L; Hong, H; Lin, X; Shi, X; Wu, Y; Zou, G | 1 |
| Abebe, KZ; Braun, WE; Brosnahan, G; Chapman, AB; Czarnecki, PG; Flessner, MF; Grantham, JJ; Harris, PC; Hogan, MC; Miskulin, DC; Moore, CG; Perrone, RD; Rahbari-Oskoui, FF; Schrier, RW; Steinman, TI; Torres, VE; Winklhofer, FT | 1 |
| Abebe, KZ; Bae, KT; Braun, WE; Brosnahan, G; Chapman, AB; Czarnecki, PG; Flessner, MF; Grantham, JJ; Harris, PC; Hogan, MC; Miskulin, DC; Moore, CG; Perrone, RD; Rahbari-Oskoui, FF; Schrier, RW; Steinman, TI; Torres, VE; Winklhofer, FT | 1 |
| Aalami, OO; Ahimastos, AA; Bourke, B; Bourke, M; Cunningham, MA; Dalman, RL; Dear, AE; Fitridge, R; Golledge, J; Jaeggi, R; Kingwell, BA; Lindeman, JH; Morris, DR; Norman, PE; Pappas, E; Pinchbeck, J; Reid, CM; Stijnen, T; Walker, PJ | 1 |
| Alter, M; Ando, R; Antonenko, V; Chaykovska, L; Hasan, AA; Hocher, B; Klein, T; Okuda, S; Rahnenführer, J; Reichetzeder, C; Sharkovska, Y; Tammen, H; Tsuprykov, O; Ueda, S; von Websky, K; Yamagishi, SI | 1 |
| El-Kadem, AH; El-Mahdy, NA; El-Sayad, ME | 1 |
| Barzilay, J; Clase, CM; Gao, P; Mann, JF; Schmieder, RE; Smyth, A; Teo, KK; Tobe, S; Yusuf, S | 1 |
| Babazono, T; Haneda, M; Ito, S; Iwamoto, Y; Katayama, S; Kawamori, R; Makino, H; Moriya, T; Takeuchi, M | 1 |
| Cohn, JN | 1 |
| Kanayama, M; Kawai, K; Kudo, H; Mann, DA; Morita, S; Nakayama, Y; Oya, T; Sasahara, M; Sugiyama, T; Takahara, T; Yata, Y | 1 |
| Avezum, A; Cardona-Munoz, E; Dagenais, GR; Diaz, R; Dyal, L; Fodor, G; Maillon, JM; Mann, JF; McQueen, MJ; Pogue, J; Probstfield, JL; Rydén, L; Schmieder, RE; Schumacher, H; Teo, KK; Wang, X; Yu, CM; Yusuf, S | 1 |
| Chaisuvannarat, V; Krairittichai, U | 1 |
| Mazerska, M; Myśliwiec, M | 1 |
| Bakris, GL; Kalaitzidis, R | 1 |
| Remuzzi, G; Ruggenenti, P | 1 |
| Baumhäkel, M; Böhm, M; Mahfoud, F; Werner, C | 1 |
| Fujimura, T; Fushida, S; Hayashi, H; Kayahara, M; Kitagawa, H; Nakagawara, H; Nakanuma, S; Ohnishi, I; Ohta, T; Okamoto, K; Tajima, H; Takamura, H; Tani, T | 1 |
| Akaike, M; Bando, S; Hirata, Y; Iwase, T; Koshiba, K; Kusunose, K; Niki, T; Sata, M; Soeki, T; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
| Chachibaia, ZK; Kuznetsova, GV; Panacheva, LA; Shpagina, LA; Ziubina, LIu; Zueva, MA | 1 |
| Balakumar, P; Bishnoi, HK; Mahadevan, N | 1 |
| Blatchford, J; Demchuk, AM; Diehl, A; Diener, HC; Forsting, M; Gizewski, ER; Hermansson, K; Möller-Hartmann, C; Sacco, RL; Saver, JL; Wanke, I; Warach, S; Weber, R; Weimar, C | 1 |
| Ismail, E; Lotfy, A; Soliman, A; Zamil, S | 1 |
| Bednarski, R; Donderski, R; Heleniak, Z; Lizakowski, S; Manitius, J; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Sulikowska, B; Tylicki, L | 1 |
| Luño, J | 1 |
| Imaizumi, T; Jinnouchi, Y; Matsui, T; Nakamura, K; Nakamura, Y; Takenaka, K; Yamagishi, S | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Aleksandrowicz, E; Larczyński, W; Lysiak-Szydlowska, W; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L | 1 |
6 review(s) available for telmisartan and Disease Exacerbation
| Article | Year |
|---|---|
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Humans; Receptor, Angiotensin, Type 1; Telmisartan; Valsartan | 2018 |
Do angiotensin receptor blockers protect against Alzheimer's disease?
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Cerebrovascular Circulation; Clinical Trials as Topic; Cognition; Disease Progression; Humans; Oxidative Stress; Phosphorylation; Telmisartan | 2013 |
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Humans; Kidney; Kidney Diseases; Mice; Obesity; Oxidative Stress; Perindopril; Renal Insufficiency, Chronic; Telmisartan | 2014 |
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Disease Progression; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome | 2010 |
Telmisartan in the management of diabetic nephropathy: a contemporary view.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus; Diabetic Nephropathies; Disease Progression; Female; Humans; Hypertension; Kidney Diseases; Male; Telmisartan; Treatment Outcome | 2012 |
[Renin-angiotensin system in diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Homeostasis; Humans; Lisinopril; Losartan; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Telmisartan | 2005 |
16 trial(s) available for telmisartan and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of Telmisartan to Slow Growth of Small Abdominal Aortic Aneurysms: A Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm, Abdominal; Disease Progression; Double-Blind Method; Female; Humans; Male; Telmisartan; Treatment Outcome | 2020 |
Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cognitive Dysfunction; Disease Progression; Double-Blind Method; Essential Hypertension; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukoencephalopathies; Male; Middle Aged; Rosuvastatin Calcium; Telmisartan | 2019 |
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diet; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feeding Behavior; Female; Follow-Up Studies; Global Health; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Prospective Studies; Ramipril; Renal Insufficiency, Chronic; Risk Factors; Telmisartan; Time Factors | 2013 |
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney Failure, Chronic; Lisinopril; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Telmisartan; Young Adult | 2014 |
Blood pressure in early autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Lisinopril; Male; Middle Aged; Organ Size; Polycystic Kidney, Autosomal Dominant; Telmisartan; Young Adult | 2014 |
TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol for a randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Aneurysm, Abdominal; Aortography; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Clinical Protocols; Disease Progression; Double-Blind Method; Humans; Intention to Treat Analysis; Quality of Life; Queensland; Research Design; Telmisartan; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Odds Ratio; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan; Time Factors; Treatment Outcome | 2017 |
Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATI
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Humans; Hypertension, Renal; Japan; Male; Middle Aged; Telmisartan; Treatment Outcome | 2008 |
Effect of telmisartan on renal outcomes: a randomized trial.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Coronary Artery Disease; Creatinine; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Risk Factors; Telmisartan | 2009 |
Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Synergism; Drug Therapy, Combination; Enalapril; Female; Humans; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2009 |
Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
Topics: Aged; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Pilot Projects; Telmisartan | 2009 |
Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Topics: Adiponectin; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Stenosis; Diabetes Mellitus, Type 2; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Neointima; Prospective Studies; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography, Interventional; Valine; Valsartan | 2011 |
Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; Brain; Disease Progression; Female; Follow-Up Studies; Humans; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Telmisartan; Treatment Outcome | 2012 |
Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Egypt; Glomerular Filtration Rate; Humans; Kidney; Magnetic Resonance Imaging; Organ Size; Polycystic Kidney, Autosomal Dominant; Protein Kinase Inhibitors; Sirolimus; Telmisartan; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.
Topics: Adult; Albuminuria; Amides; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Comorbidity; Cross-Over Studies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Fumarates; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Severity of Illness Index; Spironolactone; Telmisartan; Treatment Outcome | 2012 |
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Chronic Disease; Cilazapril; Collagen Type III; Cross-Over Studies; Disease Progression; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Potassium; Proteinuria; Renin-Angiotensin System; Spironolactone; Telmisartan | 2008 |
13 other study(ies) available for telmisartan and Disease Exacerbation
| Article | Year |
|---|---|
TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Disease Progression; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Male; NFATC Transcription Factors; Rats; Rats, Inbred SHR; Signal Transduction; Telmisartan; TRPC Cation Channels | 2015 |
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Chromatography, Liquid; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Fibrosis; Kidney; Linagliptin; Male; Mass Spectrometry; Nephrectomy; Rats, Inbred F344; Rats, Sprague-Dawley; Rats, Transgenic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Signal Transduction; Telmisartan; Time Factors | 2016 |
Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Glycation End Products, Advanced; Interleukin-1beta; Kidney; Nitric Oxide; Proteinuria; Rats; Sildenafil Citrate; Streptozocin; Superoxide Dismutase; Telmisartan; Transforming Growth Factor beta1 | 2016 |
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan; Treatment Outcome | 2008 |
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cell Line; Cell Size; Chemokine CCL2; Choline Deficiency; Collagen Type I; Disease Models, Animal; Disease Progression; Drinking; Eating; Fatty Liver; Intra-Abdominal Fat; Liver; Liver Cirrhosis; Macrophages; Male; Methionine; Mice; Mice, Inbred C57BL; Organ Size; Oxidative Stress; Receptors, CCR2; RNA, Messenger; Telmisartan; Transforming Growth Factor beta1; Triglycerides | 2009 |
Telmisartan did not prevent renal disease in patients without proteinuria.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Coronary Artery Disease; Creatinine; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Risk Factors; Telmisartan | 2009 |
Effects of angiotensin II receptor blockers on diabetic nephropathy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetic Neuropathies; Disease Progression; Humans; Kaplan-Meier Estimate; Kidney; Proteinuria; Telmisartan | 2009 |
Proteinuria: Is the ONTARGET renal substudy actually off target?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Disease Progression; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney; Multicenter Studies as Topic; Proteinuria; Ramipril; Randomized Controlled Trials as Topic; Telmisartan | 2009 |
[The role of renin-angiotensin system independent angiotensin II production in progression and fibrosis of intrahepatic cholangiocarcinoma].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; Fibrosis; Hepatic Stellate Cells; Humans; Receptor, Angiotensin, Type 1; Telmisartan | 2010 |
Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Sinus; Disease Progression; Drug Monitoring; Female; Humans; Inflammation Mediators; Male; Middle Aged; Plaque, Atherosclerotic; Serum Amyloid P-Component; Severity of Illness Index; Telmisartan; Tomography, Spiral Computed | 2011 |
[State of hepatolienal circulation and liver functions in vibration disease under angioprotector treatment].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Disease Progression; Follow-Up Studies; Hand-Arm Vibration Syndrome; Hemodynamics; Humans; Liver; Microcirculation; Middle Aged; Neovascularization, Physiologic; Occupational Exposure; Recovery of Function; Regional Blood Flow; Spleen; Telmisartan; Ultrasonography, Doppler, Color; Vasoconstriction | 2011 |
Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
Topics: Administration, Oral; Age Factors; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antioxidants; Benzimidazoles; Benzoates; Blotting, Western; Coronary Artery Disease; Disease Progression; DNA Primers; Endothelial Cells; Endothelium, Vascular; Female; Humans; Hypertension; Male; Microcirculation; Middle Aged; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telmisartan; Time Factors; Up-Regulation | 2005 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |